The MUHC Foundation welcomes new board members
Eight distinguished business and community leaders joined the MUHC Foundation’s Board of Directors in 2022. The MUHC Foundation welcomes new...
Year: 2023
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System
Wound care professionals across multiple specialties to support strategic alignment of patient, payor, and provider goalsFRAMINGHAM, Mass., Jan. 18, 2023...
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
Preliminary full year revenue for 2022 of approximately $ 2.7 million is within most recent guidance rangeCash position as of...
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
KemPharm advancing multicenter Phase 2 clinical trial investigating the efficacy and safety of KP1077 for the treatment of idiopathic hypersomnia...
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 18,...
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease First Alzheimer’s...
Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)
National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin...
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma
Figure Initial treatment imaging from first patient treated in the ReSPECT-GBM Phase 2b trialAUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE)...
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing...
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
PITTSBURGH, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing...
Quris-AI and MBZUAI to launch world-class Bio-AI center in Abu-Dhabi
Abu Dhabi-based collaboration to focus on accelerating the development of new personalized medications using AIABU DHABI, United Arab Emirates, Jan....
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study157 participants successfully randomized into the Clinical StudyPlans in place...
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
Patient Access Initiative Addresses €1 Billion Annual Market in GermanyBERKELEY, US and MAINZ, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) --...
Nicox Provides Fourth Quarter 2022 Financial Highlights
Press ReleaseNicox Provides Fourth Quarter 2022 Financial HighlightsNet revenue €1.0 million for fourth quarter 2022, and €3.3 million for the...
BioSenic appoints Dr Carole Nicco as Chief Scientific Officer
Dr Nicco will oversee the development of pipeline across BioSenic’s cell therapy and autoimmune disease platform and will be responsible...
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving...
Junshi Biosciences Announces Acceptance of NDA for VV116 in China
SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study
SHANGHAI, China, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
Burning Rock provides an update on 2022 revenue guidance
GUANGZHOU, China, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or...
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology...